Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Potential therapeutic action of nitrite in sickle cell disease
source: Redox Biology
year: 2017
authors: Wajih N, Basu S, Jailwala A, Kim HW, Ostrowski D, Perlegas A, Bolden CA, Buechler NL, Gladwin MT, Caudell DL, Rahbar E, Alexander-Miller MA, Vachharajani V, Kim-Shapiro DB
summary/abstract:Sickle cell disease is caused by a mutant form of hemoglobin that polymerizes under hypoxic conditions, increasing rigidity, fragility, calcium influx-mediated dehydration, and adhesivity of red blood cells. Increased red cell fragility results in hemolysis, which reduces nitric oxide (NO) bioavailability, and induces platelet activation and inflammation leading to adhesion of circulating blood cells. Nitric Oxide inhibits adhesion and platelet activation. Nitrite has emerged as an attractive therapeutic agent that targets delivery of NO activity to areas of hypoxia through bioactivation by deoxygenated red blood cell hemoglobin.
In this study, we demonstrate anti-platelet activity of nitrite at doses achievable through dietary interventions with comparison to similar doses with other NO donating agents. Unlike other NO donating agents, nitrite activity is shown to be potentiated in the presence of red blood cells in hypoxic conditions. We also show that nitrite reduces calcium associated loss of phospholipid asymmetry that is associated with increased red cell adhesion, and that red cell deformability is also improved. We show that nitrite inhibits red cell adhesion in a microfluidic flow-channel assay after endothelial cell activation.
In further investigations, we show that leukocyte and platelet adhesion is blunted in nitrite-fed wild type mice compared to control after either lipopolysaccharide- or hemolysis-induced inflammation. Moreover, we demonstrate that nitrite treatment results in a reduction in adhesion of circulating blood cells and reduced red blood cell hemolysis in humanized transgenic sickle cell mice subjected to local hypoxia. These data suggest that nitrite is an effective anti-platelet and anti-adhesion agent that is activated by red blood cells, with enhanced potency under physiological hypoxia and in venous blood that may be useful therapeutically.
organization: Wake Forest University, Winston-Salem, NC; University of Pittsburgh, Pittsburgh, PA; Wake Forest University School of Medicine, Winston-Salem, NCDOI: 10.1016/j.redox.2017.05.006
read more full text
+myBinderRelated Content
-
Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial showsTreatment with Endari (L-glutamine) le...
-
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
-
ASH launches sickle cell disease clinical trials network to accelerate therapy developmentASH launched a clinical trials network d...
-
Mount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatmentThe Departments of Emergency Medicine an...
-
Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemiaSilent cerebral infarction (SCI) is the ...
-
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Effi...Background: Hydroxyurea prevents disea...
-
Sickle Cell Foundation Nigeria, Rhieos Develop 1st Multi-SCD Registry in NigeriaIn a bid to improve quality of care for ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.